cystic fibrosis

Nov 06, 2024

The advent of organoid technology has marked a revolutionary milestone in biomedical research and healthcare. Organoids, which are three-dimensional structures derived from stem cells that mimic the architecture and functionality of specific organs, have opened new avenues for understanding diseases, testing drugs,...

Jan 12, 2024

Cystic Fibrosis impacts approximately 1 in every 3,500 births, with around 70,000 affected individuals globally, and 31,000 in the United States alone. Those with the condition experience the development of dense, adhesive mucus in their lungs, making them prone to infections. Over time, this leads to inflammation ...

Nov 28, 2023

Dupixent Significantly Reduced COPD Exacerbations In Second Positive Phase III Trial The latest trial for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD), called NOTUS, has delivered promising results. It showed a significant 34% reduction in COPD exacerbations, confirming earlier positive f...

Dec 13, 2022

Amgen Inc. Agrees to Purchase Dublin-based Horizon Therapeutics Plc. for €24.7 Billion  Amgen Inc. has agreed to buy Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26 billion), in a deal that could face further delays or a breakdown in negotiations. Following Sanofi's withdrawal from the race, c...

May 26, 2021

Today, the increasing prevalence of Chronic Respiratory Diseases (CRDs) is one of the leading health challenges worldwide. CRDs affect hundreds of millions of people and cause huge mortality, morbidity, immense socio-economic burden, and disability-adjusted life years (DALYs).  Over the past few decades, si...

Nov 26, 2020

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors in mice Several viruses have a natural ability to eliminate cancer; however translating them into treatments has proven difficult, partly due to the immune system tends to kill them before they can reach cancer cells. Researchers fr...

Mar 26, 2020

FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...

Feb 10, 2020

Slowly or rapidly growing bacteria- Nontuberculous mycobacteria (NTM), might appear innocuous, however, NTM infections have a notably higher total prevalence of 3,65,273 in the 7MM, estimates DelveInsight. Despite the global prevalence, clear from the facts and figures, the available therapies are entirely on an in...

Feb 03, 2020

Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung disorders. Especially common in the elderly, individuals with lung diseases, slender caucasian women, and people with esophageal disorders, NTM affects both healthy persons and thos...

Oct 22, 2019

The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation...